Heart failure & cardiomyopathies
Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction
Authors' conclusion
Their use was safe since associated with lower mortality and morbidity.
Study context
- Population
- Patients with HF with mildly reduced EF (heart failure with mildly reduced ejection fraction (HFmrEF), EF 40–49%) in the Swedish HF Registry1:1 matched cohorts
- Participants
- 12,421 patients
- Exposure
- RASI/ARNI use vs no use; beta-blocker use vs no use
- Outcome
- Cardiovascular (CV) mortality/HF hospitalization and all-cause mortality
Methodological detailspropensity-score matched, Swedish HF Registry
- Propensity-score matched
- Swedish HF Registry
Main finding
As reported in the abstract
Hazard ratio (95% CI)
RASI/ARNIvs No RASI/ARNICV mortality/HF hospitalization
0.90(0.83–0.98)
Beta-blockersvs No beta-blockersCV mortality/HF hospitalization
0.82(0.74–0.90)
RASI/ARNIvs No RASI/ARNIall-cause mortality
0.75(0.69–0.81)
Beta-blockersvs No beta-blockersall-cause mortality
0.79(0.72–0.87)
Observational data: associations, not effects.
Further findings
| Outcome | RASI/ARNI | Beta-blockers |
|---|---|---|
| Treatment use | 84% | 88% |
Treatment use
- Shared independent predictors of use: younger age, outpatient, specialty care follow-up, hypertension
Positive control (EF < 40%) and negative control outcome (cancer-related hospitalization)
- Results consistent at the positive control analysis
- No associations between treatment use and the negative control outcome
Original publication
Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction. Eur Heart J Cardiovasc Pharmacother. Published 18 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →